Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solid Biosciences Inc.

www.solidbio.com

Latest From Solid Biosciences Inc.

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race

The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.

M & A Blood & Coagulation Disorders

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital

Pfizer ended its early neuroscience R&D work earlier this year, but will retain a 25% stake in the start-up, which may begin a Phase III Parkinson's disease study in 2019. This is the second time Bain has financed a Pfizer spin-out.

Deals Financing

Sarepta Commits To Rapid, Thorough Pivotal Study For DMD Gene Therapy Based On Functional Improvements

The company presented encouraging data on functional assessments of four boys treated with a micro-dystrophin gene therapy at the World Muscle Society, furthering momentum around the program.

Rare Diseases Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Solid Ventures
  • Solid Biosciences LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Solid Biosciences Inc.
  • Senior Management
  • Ilan Ganot, CEO
    Jennifer Ziolkowski, CFO
    Carl Morris , PhD, CSO
    Joel Schneider, PhD, CTO, Head, Exploratory R&D
    Jorge A Quiroz, MD, CMO
    Alvaro Amorrortu, COO
  • Contact Info
  • Solid Biosciences Inc.
    Phone: (617) 337-4680
    161 First St.
    3rd Floor
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register